Opendata, web and dolomites

SenolT SIGNED

Fast and effective diagnostic test for the early detection of residual tumours to prevent cancer recurrence

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SenolT project word cloud

Explore the words cloud of the SenolT project. It provides you a very rough idea of what is the project "SenolT" about.

company    initial    medicines    treatment    de    radiotherapy    liquid    protein    mission    kinds    total    jobs    monitoring    therapeutics    companies    npv    contacted    prevent    pharma    slow    detection    352    tnbc    senolt    10    license    pancreatic    rate    validated    diagnostic    recurrence    triple    mortality    20    risked    newly    soon    markers    portfolio    demand    patients    44    royalties    prognosis    usa    received    cells    families    competitors    pressing    finalise    technologies    cancers    population    appear    tam    residual    healthcare    proprietary    15    damaged    hard    innovative    discount    senolytic    expensive    predict    tumour    cumulative    poor    sales    develops    mainly    net    therapies    cancer    57    breast    tests    tumours    customers    27    share    800    clinical    trials    removing    people    senescent    happen    2025    negative    irr    class    120    ebitda    pharmaceutical    biopsy    lives    phase2    market    created    detects    price    chemotherapy   

Project "SenolT" data sheet

The following table provides information about the project.

Coordinator
SENOLYTIC THERAPEUTICS SL 

Organization address
address: CL BALDIRI I REIXAC 4-8 PARC CIENTIFIC DE BARCELON
city: BARCELONA
postcode: 8028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.senolytx.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2019-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SENOLYTIC THERAPEUTICS SL ES (BARCELONA) coordinator 50˙000.00

Map

 Project objective

The main concern in cancer treatment is its high rate of recurrence. It may happen soon or years after treatment and it’s very hard to predict/prevent. Removing residual tumour cells is the best way to avoid recurrence, so identifying new tumour markers is the most pressing demand. We have developed SenolT, an innovative diagnostic test for the early detection and monitoring of senescent cells, which appear after chemotherapy/radiotherapy and are directly associated to cancer recurrence. SenolT detects all kinds of tumours, but we focus on pancreatic and triple negative breast (TNBC) cancers because prognosis is very poor for patients and recurrence is their main cause of mortality. Our customers will be pharmaceutical companies, so we have already contacted several of them in the sector. The initial target market will be TNBC/Pancreatic cancer patients that received chemotherapy/radiotherapy in the EU & USA. Competitors focus on liquid biopsy tests and cancer-related protein markers (expensive & slow to get results). No other companies are working in the detection of senescent cells as a diagnostic method to predict recurrence. Senolytic Therapeutics is a company that develops a new class of medicines by targeting damaged cells. Our mission is to advance our portfolio of therapies to clinical trials and improve the lives of patients and families. Our SenolT proprietary technology will be developed and de-risked through Phase2 Clinical trials and then license the validated technologies to pharma companies, to finalise their development and bring them to the market. By 2025 we expect: A) 15% royalties’ rate on net sales with a unit price to healthcare systems of €800; B) 20% market share (70,000 people) from an expected total of TNBC/pancreatic cancer population of over 352,000 in USA & EU; C) TAM growing up to about €57 m; D) NPV of €27.2 m (10% discount rate) and an IRR of 120%; E) Cumulative EBITDA of about €44 m; F) 20 newly created jobs, mainly in R&D and sales.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SENOLT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SENOLT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More